Journal
EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 16, Issue 10, Pages 1147-1154Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737175.2016.1197774
Keywords
Amyotrophic lateral sclerosis; hyperexcitability; riluzole; mexiletine; flecainide; retigabine; edaravone; free radical scavenger; neuroprotective
Categories
Funding
- Nakabayashi Trust for ALS research
- National Health and Medical Research Council of Australia [1037746]
Ask authors/readers for more resources
Introduction: Motor neuron hyperexcitability appears linked to the process of neurodegeneration in amyotrophic lateral sclerosis (ALS). As such, therapies that inhibit neuronal hyperexcitability may prove effective in arresting the progression of ALS.Area covered: We searched MEDLINE and ClinicalTrials.gov and selected randomised controlled trials that covered neuroprotective therapy. Riluzole has been established to reduce neuronal hyperexcitability. More recently, initial studies of Na+ channel blockers (mexiletine and flecainide) have been trialled. Separately, a trial of a K+ channel activator (retigabine) is underway, while edaravone is currently being considered for licensing by drug approval agencies based on a hypothesis that the elimination of free radicals may lead to protection of motor neurones.Expert commentary: Initial clinical trials with Na+ channel blockers have not yet established efficacy in ALS. Currently, retigabine is under evaluation as a potential therapy. Edaravone has recently been approved as a new therapeutic option for ALS in Japan.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available